"Bortezomib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA.
| Descriptor ID |
D000069286
|
| MeSH Number(s) |
D01.029.260.110.500 D01.132.285.500 D02.203.200.500 D03.383.679.450
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bortezomib".
Below are MeSH descriptors whose meaning is more specific than "Bortezomib".
This graph shows the total number of publications written about "Bortezomib" by people in this website by year, and whether "Bortezomib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 6 | 6 |
| 2016 | 2 | 1 | 3 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 2 | 3 | 5 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
| 2024 | 0 | 2 | 2 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bortezomib" by people in Profiles.
-
Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study. Lancet Haematol. 2026 Mar; 13(3):e144-e156.
-
Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024 08; 99(8):1586-1594.
-
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood. 2024 05 16; 143(20):2053-2058.
-
Efficacy of Autologous Stem Cell Transplantation for Myeloma Patients with Suboptimal Response: A Multicenter Retrospective Analysis. Transplant Cell Ther. 2023 11; 29(11):688.e1-688.e13.
-
Does Bortezomib-Dexamethasone-Rituximab-Cyclophosphamide Play a Role in the Treatment of Waldenstr?m's Macroglobulinemia? J Clin Oncol. 2023 08 20; 41(24):4059-4060.
-
Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group. Proteomics Clin Appl. 2023 11; 17(6):e2200109.
-
Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study. Haematologica. 2022 10 01; 107(10):2329-2343.
-
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022 07 01; 40(19):2106-2118.
-
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA. Proteomics Clin Appl. 2022 03; 16(2):e2100072.
-
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. Aging (Albany NY). 2021 09 10; 13(17):21102-21121.